Companies ›Healthcare ›BSX.AX

BSX.AX — ASX Advanced Medical Equipment & Technology

Blackstone Minerals Ltd

A$0,04

Open in Charts → Attach watcher ⌖

— —

AUD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

-743,6 %

ROE

-11,6 %

Net margin

-811,2 %

Debt / equity

0,00

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Blackstone Minerals Ltd is a diversified mining company operating in the basic materials sector, primarily engaged in the exploration and production of minerals.

Business. Blackstone Minerals Ltd (BSX.AX) is an Australian company listed on the Australian Securities Exchange that operates within the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products in the health care sector. Specific details regarding operating segments and geographic concentrations are not disclosed in the available data.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

Generated · model-assisted

Sell-side consensus

BUY35 analysts

28 buy7 hold0 sell

Avg 12m price target78,30

Analyst recommendations

35 analysts · consensus Buy

Buy28

Hold7

Sell0

12-month price target

78,30

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

35 analysts · indicative

Ownership

—

not yet wired

Profitability→

-11,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning BSX.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to BSX.AX. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR
Congressional trades
CongressJohn Boozman — Boston Scientific Corporation Common Stock2026-06-04 · Republican · AR · Sale · $1,001 - $15,000
CongressMarkwayne Mullin — Boston Scientific Corporation Common Stock2025-12-29 · Purchase · $15,001 - $50,000
CongressJohn Boozman — Boston Scientific Corp2025-12-17 · Republican · AR · Sale · $1,001 - $15,000
CongressLisa McClain — Boston Scientific Corporation2025-10-31 · Republican · MI · Sale · $1,001 - $15,000
CongressLisa McClain — Boston Scientific Corporation2025-10-30 · Republican · MI · Sale · $1,001 - $15,000
CongressLisa McClain — Boston Scientific Corporation2025-10-30 · Republican · MI · Purchase · $1,001 - $15,000

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Blackstone Minerals Ltd (BSX.AX) is an Australian company listed on the Australian Securities Exchange that operates within the Advanced Medical Equipment & Technology industry. The firm generates revenue through the sale of products in the health care sector. Specific details regarding operating segments and geographic concentrations are not disclosed in the available data.

Classification99 %

SectorHealth Care

Industry groupAdvanced Medical Equipment & Technology

AI synthesis

GENERATED

Blackstone Minerals Ltd has a negative return on equity of -11.56% and a negative return on assets of -11.63%, indicating poor capital efficiency and asset utilization. The company's liquidity position is assessed as medium, with a current ratio of 0.3, suggesting limited short-term liquidity to cover immediate obligations. The company has no long-term debt, but its operating cash flow is negative at -5,844,610 AUD, and free cash flow is also negative at -9,234,760 AUD, indicating ongoing cash outflows.

The company's profitability is severely underperforming, with a net loss of -9,724,530 AUD and an operating loss of -8,913,920 AUD. These figures are significantly below the industry median for profitability metrics, highlighting a challenging operational environment. The negative gross profit of -780,510 AUD further underscores the company's inability to generate profit from its core operations.

Blackstone Minerals Ltd's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification reported. This lack of diversification increases the company's exposure to regional economic and regulatory risks. The company's revenue is entirely derived from its mining operations, with no disclosed segments or geographic breakdown.

The company's growth trajectory is negative, with a significant decline in revenue and profitability. The outlook for the current fiscal year indicates a continuation of this trend, with no signs of improvement in the near term. The company's capital expenditure of -111,910 AUD suggests minimal investment in growth initiatives, further limiting its ability to improve performance.

The company's risk assessment indicates a medium liquidity risk, primarily due to its negative operating cash flow and free cash flow. The risk of dilution is assessed as low, with no significant dilution events reported in the recent financial statements. The company's total liabilities are negative at -492,770 AUD, indicating a net cash position, but this is offset by the absence of long-term debt.

Recent events, including financial filings and transcripts, indicate ongoing operational challenges and a lack of strategic direction. The company has not disclosed any material events or strategic initiatives that could improve its financial performance in the near term.

Key takeaways

Blackstone Minerals Ltd is experiencing significant financial distress, with negative returns on equity and assets.
The company's liquidity position is weak, with a current ratio of 0.3 and negative operating and free cash flows.
The company's profitability is severely underperforming, with a net loss of -9,724,530 AUD and an operating loss of -8,913,920 AUD.
The company lacks geographic and segment diversification, increasing its exposure to regional risks.
The company's growth trajectory is negative, with no signs of improvement in the near term.
The risk of dilution is low, but the company's liquidity risk remains a concern.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

A$0,04

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

A$84.1M

Net cashⓘ

-A$241.6k

Current ratioⓘ

0.3

Debt / equityⓘ

0.0

ROAⓘ

-11.6%

ROEⓘ

-11.6%

Cash conversionⓘ

60.0%

CapEx / revenueⓘ

-9.3%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Cardiovascular Devices66,0 %

disclosed · sec_xbrl · 2025-12-31

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison7 peers · vs BSX · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

— vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

— vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

— vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

— vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

— vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

— vs self

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

3,36

Predicted surprise

-0,05

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-06-25 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Corporate eventM&A horizon

M&A probabilityconf 3 %

Probability

3 %

Base rate

3 %

Band

—

180-day horizon · target 2027-01-19 · 1,0× base rate

No acquirer candidates identified by the signal model.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

LowA$55,00

MeanA$78,30

MedianA$75,00

HighA$118,00

SpotA$0,04

+205946.6 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

Op Margin-743,6 %Bottom quartile

Net Margin-811,2 %Bottom quartile

ROE-11,6 %Below median

Capex / Rev-9,3 %Below median

D/E0,00Above median

Cash Conv0,60Below median

Corporate actions / M&A

M&A probabilityconf —

Probability

3 %

Base rate

3 %

Band

Low

180-day horizon · target 2027-01-19 · 1,0× base rate

No acquirer candidates identified by the signal model.

Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 2 518 sh10 exercises · 8 grants7 insiders

Monson JonathanEVP and CFO · Restricted Stock Units → Common StockDisposed 2 087exercise · 2026-07-01
Smith Cathy RDirector · Deferred Stock Units → Common StockAcquired 3 800grant · 2026-05-07
Pegus CherylDirector · Deferred Stock Units → Common StockAcquired 3 800grant · 2026-05-07
Pegus CherylDirector · Deferred Stock Units → Common StockAcquired 1 281grant · 2026-05-07
Smith Cathy RDirector · Deferred Stock Units → Common StockAcquired 2 209grant · 2026-05-07
Weber Christophe PierreDirector · Deferred Stock Units → Common StockAcquired 2 660grant · 2026-05-07
O'Connor Padraig AndrewEVP, Global Operations · Restricted Stock Units → Common StockDisposed 1 802exercise · 2026-05-02
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC · Restricted Stock Units → Common StockDisposed 2 102exercise · 2026-05-02
Smith Cathy RDirector · Deferred Stock Units → Common StockAcquired 323grant · 2026-03-02
Smith Cathy RDirector · Deferred Stock Units → Common StockAcquired 556grant · 2026-03-02
Pegus CherylDirector · Deferred Stock Units → Common StockAcquired 24grant · 2026-03-02
Woodworth EmilySVP, Global Controller and CAO · Restricted Stock Units → Common StockDisposed 838exercise · 2026-03-01
Woodworth EmilySVP, Global Controller and CAO · Restricted Stock Units → Common StockDisposed 637exercise · 2026-02-16
O'Connor Padraig AndrewEVP, Global Operations · Restricted Stock Units → Common StockDisposed 905exercise · 2026-02-16
Woodworth EmilySVP, Global Controller and CAO · Restricted Stock Units → Common StockDisposed 661exercise · 2026-02-14
O'Connor Padraig AndrewEVP, Global Operations · Restricted Stock Units → Common StockDisposed 1 190exercise · 2026-02-14
O'Connor Padraig AndrewEVP, Global Operations · Restricted Stock Units → Common StockDisposed 500exercise · 2026-02-13
Woodworth EmilySVP, Global Controller and CAO · Restricted Stock Units → Common StockDisposed 1 413exercise · 2026-02-13

Physical assets

2 tracked

Asset	Type	Commodity	Country	Role
Ban Phuc	Other	Copper	Vietnam	Operating company
Ban Phuc	Mine	Copper	Vietnam	Operating company

Tracked physical assets associated with this issuer (operated, managed, or owned).

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Capex To Revenue
capital_expenditure / revenue
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income

Source documents

Blackstone Minerals Ltd Market data — financials · 2026-05-27

Ownership & reference

Insider activity

Net buying5 buys · 0 sellsnet $781K14 insiders · last 365d

Fitzgerald Joseph MichaelEVP & Group Pres, Cardiology · Common StockOther 64 198 @ $46,73$3,0M · 2026-07-31
LUDWIG EDWARD JDirector · Common StockBought 5 000 @ $45,48$227K · 2026-07-31
Monson JonathanEVP and CFO · Common StockOther 1 010 @ $43,06$43K · 2026-07-01
Monson JonathanEVP and CFO · Common StockOther 2 087 · 2026-07-01
Mahoney Michael FDirector, Chairman, President & CEO · Common StockOther 386 755 · 2026-05-28
LUDWIG EDWARD JDirector · Common StockBought 3 580 @ $56,68$203K · 2026-05-20
Habiger David CDirector · Common StockBought 2 250 @ $55,92$126K · 2026-05-20
Pegus CherylDirector · Common StockBought 1 770 @ $56,49$100K · 2026-05-20
Habiger David CDirector · Common StockBought 2 200 @ $56,95$125K · 2026-05-19
WICHMANN DAVID SDirector · Common StockOther 3 800 · 2026-05-07
Weber Christophe PierreDirector · Common StockOther 1 767 · 2026-05-07
Weber Christophe PierreDirector · Common StockOther 1 140 · 2026-05-07
Morano Susan EDirector · Common StockOther 3 800 · 2026-05-07
Zane Ellen MDirector · Common StockOther 3 800 · 2026-05-07
Mega Jessica LDirector · Common StockOther 3 800 · 2026-05-07
LUDWIG EDWARD JDirector · Common StockOther 3 800 · 2026-05-07
Habiger David CDirector · Common StockOther 3 800 · 2026-05-07
Morano Susan EDirector · Common StockOther 1 281 · 2026-05-07
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC · Common StockOther 2 102 · 2026-05-02
O'Connor Padraig AndrewEVP, Global Operations · Common StockOther 1 802 · 2026-05-02
O'Connor Padraig AndrewEVP, Global Operations · Common StockOther 872 @ $56,50$49K · 2026-05-02
Butcher Arthur CEVP& Grp Pres, MedSurg & APAC · Common StockOther 1 007 @ $56,50$57K · 2026-05-02
Weber Christophe PierreDirector · Common StockOther 556 · 2026-03-02
Morano Susan EDirector · Common StockOther 24 · 2026-03-02
Weber Christophe PierreDirector · Common StockOther 323 · 2026-03-02

Short positioning

28.3Mshares short+1.2% vs prior

1.69days to cover

39.0%short of daily vol

13.8Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Index membership

S&P 500United States

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

BSX.AXCanonical

ASX · AUD

Intel & risk

PredictorBeat prob45 %Surprise-0,05M&A prob3 %Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

Capex (YoY) (2025-12-31 vs 2024-12-31): 10.9%Derived (calculated)
Current ratio (FY 2025-12-31): 1.62xDerived (calculated)
Gross margin (FY 2025-12-31): 69.0%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 11.3%Derived (calculated)
Revenue (YoY) (2025-12-31 vs 2024-12-31): 19.9%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): 38.8%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 10.9%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 32.0%Derived (calculated)
Gross profit (YoY) (2025-12-31 vs 2024-12-31): 20.6%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 55.2%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 55.6%Derived (calculated)
Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 18.3%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 374.6%Derived (calculated)
Total operating expenses (annual): USD 10.24BSEC XBRL filing
Pre-tax income (annual): USD 3.38BSEC XBRL filing
Cost of revenue (annual): USD 6.22BSEC XBRL filing
Cash & equivalents (annual): USD 1.97BSEC XBRL filing
Interest expense (annual): USD 349MSEC XBRL filing
Operating cash flow (annual): USD 4.53BSEC XBRL filing
Revenue (annual): USD 20.07BSEC XBRL filing
Shareholders' equity (annual): USD 24.23BSEC XBRL filing
Capex (annual): USD 876MSEC XBRL filing
Operating income (annual): USD 3.61BSEC XBRL filing
EPS (basic) (annual): USD-PER-SHARES 2SEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-30 04:36 UTCFILINGMaterial 8-K

2026-07-29 00:00 UTCTRANSCRIPTEarnings call — Q3 2026

2026-07-28 04:34 UTCFILINGMaterial 8-K

2026-07-13CONGRESSJohn Boozman (senate) sale shares → $1,001 - $15,000

2026-07-01INSIDERMonson Jonathan transacted 1.0k sh — EVP and CFO ~$43k

2026-07-01INSIDERMonson Jonathan transacted 2.1k sh — EVP and CFO

2026-07-01INSIDERMonson Jonathan disposed of 2.1k sh Restricted Stock Units — EVP and CFO

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)

2026-06-24 03:12 UTCHOLDERInstitutional holding changed

2026-06-24 03:12 UTCHOLDER1 institutional position change flagged (1 major)

2026-06-21 02:57 UTCHOLDERInstitutional holding changed

2026-06-21 02:57 UTCHOLDER1 institutional position change flagged (1 major)

2026-05-28 00:00 UTCINSIDER25 insider transactions — 2026-05 · net buy $448k 7 derivative

2026-05-28INSIDERMahoney Michael F transacted 386.8k sh — Director, Chairman, President & CEO

2026-05-20INSIDERLUDWIG EDWARD J bought 3.6k sh — Director ~$203k

2026-05-20INSIDERHabiger David C bought 2.2k sh — Director ~$126k

2026-05-20INSIDERPegus Cheryl bought 1.8k sh — Director ~$100k

2026-05-19INSIDERHabiger David C bought 2.2k sh — Director ~$125k

2026-05-18FILING8-K filing →

2026-05-07INSIDERWICHMANN DAVID S transacted 3.8k sh — Director

2026-05-07INSIDERWeber Christophe Pierre transacted 1.8k sh — Director

2026-05-07INSIDERWeber Christophe Pierre transacted 1.1k sh — Director

2026-05-07INSIDERMorano Susan E transacted 3.8k sh — Director

2026-05-07INSIDERZane Ellen M transacted 3.8k sh — Director

2026-05-07INSIDERMega Jessica L transacted 3.8k sh — Director

2026-05-07INSIDERLUDWIG EDWARD J transacted 3.8k sh — Director

2026-05-07INSIDERHabiger David C transacted 3.8k sh — Director

2026-05-07INSIDERMorano Susan E transacted 1.3k sh — Director

2026-05-07INSIDERWeber Christophe Pierre acquired 2.7k sh Deferred Stock Units — Director

2026-05-07INSIDERPegus Cheryl acquired 3.8k sh Deferred Stock Units — Director

2026-05-07INSIDERSmith Cathy R acquired 2.2k sh Deferred Stock Units — Director

2026-05-07INSIDERSmith Cathy R acquired 3.8k sh Deferred Stock Units — Director

2026-05-07INSIDERPegus Cheryl acquired 1.3k sh Deferred Stock Units — Director

2026-05-05FILING8-K filing →

2026-05-02INSIDERButcher Arthur C transacted 2.1k sh — EVP& Grp Pres, MedSurg & APAC

2026-05-02INSIDERO'Connor Padraig Andrew transacted 1.8k sh — EVP, Global Operations

Showing the 40 most recent of 85 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Physical assets

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread